Details of the Drug Reposition

General Information of This Drug (ID: DMIW5P1)

Drug Name
BPM 31510   DMIW5P1
Drug Type
Lipid-drug conjugate

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Glioma DIS5RPEH 2A00.0 Phase 2 [1]
Pancreatic cancer DISJC981 2C10 Phase 2 [2]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Epidermolysis bullosa DISVOTZQ EC3Z Phase 1 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04752813) A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02650804) A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients. U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT02793960) Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa. U.S. National Institutes of Health.